


# The SARA-ICE Model for Predicting Skin Sensitizer Potency

Emily N. Reinke<sup>1</sup> and Nicola Gilmour<sup>2</sup>

<sup>1</sup>Inotiv, Inc., in support of National Toxicology Program Interagency Center for the Evaluation of Alternative Test Methods (NICEATM) and <sup>2</sup>Unilever, Safety, Environmental and Regulatory Science

1st July 2025







Section 1 – SARA-ICE Basics

What is in the database Input data options

Data output




Section 2 – Using SARA-ICE

Guideline 497 PoD
Web Platform Walkthrough



# **SARA-ICE Basics**






### OECD Defined Approaches (DAs) for Skin Sensitisation (TG 497)

- In 2021, OECD Test Guideline 497 was adopted.
- TG 497 meets regulatory requirements for:
  - DAs that discriminate between sensitizers and non-sensitizers
  - DAs that discriminate strong from weak/moderate sensitizers (i.e., GHS potency categories)

- In 2021, the US and UK began a joint led feasibility study project under OECD for evaluating a defined approach that can provide a point of departure for quantitative risk assessment
- In 2024, the project began drafting an update to OECD TG 497 to incorporate DAs for PoD determination (i.e. SARA-ICE), expected to be released mid-2025.
- In parallel, a self-contained version of the model and user interface have been developed, accessed via NICEATMs website.







#### SARA-ICE DA (OECD TG 497 Version)

Input

#### In vivo HPPT, LLNA ED<sub>01</sub> (1% Bayesian statistical **SARA-ICE PoD** sensitising model (SARA-ICE) dose in HPPT) In vitro **OECD** TG SARA-ICE model: Continuous measure of SARA-ICE PoD

#### SARA-ICE database:


434 chemicals 1,407 in vivo studies 2,575 in vitro studies Network of probability distributions to describe associations between all data types

## sensitiser potency

Probability distribution of a random variable defined as the dermal dose required to induce sensitisation in 1% of a HPPT-eligible population.

This is a singlevalued quantity at a physically possible dose that may serve as a suitable value for input into exposure-based risk assessment.






#### The SARA-ICE database

Study type	НРРТ	LLNA	DPRA	kDPRA	KeratinoSens	h-CLAT	U-Sens
Inputs into SARA- ICE	Dermal dose, number tested, number sensitised	EC <sub>3</sub> or maximum concentration tested if no response observed	% depletion of cysteine and lysine peptides	Log Kmax	EC <sub>1.5</sub> or maximum concentration tested IC50 or maximum concentration tested	CD86 EC <sub>150</sub> , CD50 EC <sub>200</sub> or maximum concentration tested CV <sub>75</sub> or maximum concentration tested	CD86 EC <sub>150</sub> or maximum concentration tested CV <sub>75</sub> or maximum concentration tested
Number of studies in database	871	536	650	361	972	428	164
Number of unique CASRN with this study type	276	195	251	185	258	211	90






#### **Data Input Options**

Data Type (minimum 1)	Specific Metric(s) Required*	OECD Test Guideline	
Human predictive patch test (HPPT)	Dermal dose (μg/cm²), N test subjects, N test subjects sensitized	N/A	
Murine local lymph node assay (LLNA)	EC3 (percent)	<u>TG 429</u>	
Direct peptide reactivity assay (DPRA)	Percent depletion (Cys and/or Lys)	TG 442C	
Kinetic DPRA (kDPRA)	log kmax (units/M-s)	TG 442C	
KeratinoSens™	EC <sub>1.5</sub> and IC <sub>50</sub> (μM) Or maximum dose tested	TG 442D	
Human cell line activation test (h-CLAT)	EC200 (CD54), EC150 (CD86), CV75 (μg/mL) Or maximum dose tested	TG 442E	
U-SENS™	EC150 and CV70 (μg/mL) Or maximum dose tested	TG 442E	

<sup>\*</sup>All metrics are required for an individual data type, or the model will not run

Predictions can be made on partial data sets, minimum of two data types required






#### SARA-ICE DA (OECD TG 497 Version)

- SARA-ICE estimates a human-relevant metric of sensitiser potency defined as the HPPT 1% sensitising dose (ED<sub>01</sub>).
- This model derives the PoD from the ED<sub>01</sub> distribution and expresses it as a value in μg/cm<sup>2</sup> that can be used subsequently for a risk assessment.
  - The PoD is defined as the geometric mean of the distribution.
- Acceptable for use under MAD
- Presumes that the substance under evaluation by the model is a skin sensitizer
  - The range of the ED<sub>01</sub> distribution has an upper limit of 60,000 μg/cm<sup>2</sup> (highest dose used in an HPPT).
  - Distribution is centered on the 90% credible interval (interval between the 5th and 95th percentiles of the distribution)



# **Using SARA-ICE**





#### Access to the tool

 https://ntp.niehs.nih.gov/whatwestudy/niceatm/test-method-evaluations/skinsens/da/SARA-ICE





Click here to enter the tool


#### **Access the SARA-ICE Tool**

<u>Download SARA-ICE Template File for use in the tool</u>

There is an international need for non-animal approaches to identify potential skin sensitizers. While <u>defined approaches</u> (DAs) are accepted for making a binary prediction of whether or not a substance might be a skin sensitizer (as described in <u>OECD Guideline 497</u> &), there remains a need for non-animal approaches for quantitative prediction of skin sensitizer potency.


The Skin Sensitization Risk Assessment – Integrated Chemical Environment (<u>SARA-ICE</u>) DA is a Bayesian statistical model developed in a collaboration between <u>NICEATM</u> and the consumer products company Unilever. SARA-ICE estimates a human-relevant metric of skin sensitizer potency. This metric, termed ED01, is the dose with a 1% chance of human skin sensitization (<u>Reinke et al. 2025</u>). SARA-ICE uses data on over 400 chemicals from the NICEATM <u>Integrated Chemical Environment</u> (ICE) to predict a point-of-departure using any combination of in vivo (human predictive patch test or local lymph node assay) and in vitro (direct peptide reactivity assay [DPRA], kinetic DPRA, Keratino Sens™ human cell line activation test or IL-SENS™) data






clicking "Next" below input field

#### **General Layout**









#### **Overview Page**

- Steps for use:
  - Read the directions
  - Access resources if needed
  - To advance, click "Next" at the bottom of the page or "Select Input File" in the top menu
- Resources available on this page:
  - User Guide (downloadable PDF)
  - Workflow instructions
  - Help & Support link
    - Available at <a href="mailto:ICE-support@niehs.nih.gov">ICE-support@niehs.nih.gov</a>




Next >





#### Select Input File Page


- Steps for use:
  - Download Template
    - This template provides the required formatting for data input into the models. Models will not run if this formatting is not followed.
  - Select Data Input File
    - Drag and drop completed data input file or browse to upload file.
  - Click "Next" or "Select Model" (top of page)
- Resources
  - Blank Template
  - Example File use to demonstrate tool






#### **Populating the Data Template File**

- "Key" tab provides instructions on what data are required for each input type.
- Use the SARA-ICE Example File if unsure how data should be entered.
- Do not change header names in the template: the model will not run if these are altered.
- Limit entries (such as "<x", ">x") are permitted.
- Substance names/ CAS RNs must be manually entered on each tab
- Molecular weight is required if kDPRA or KeratinoSens data are entered.







# **Data Input Options**

Data Type (minimum 1)	Specific Metric(s) Required*	OECD Test Guideline
Human predictive patch test (HPPT)	Dermal dose (µg/cm²), N test subjects, N test subjects sensitized	N/A
Murine local lymph node assay (LLNA)	EC3 (percent)	TG 429
Direct peptide reactivity assay (DPRA)	Percent depletion (Cys and/or Lys)	TG 442C
Kinetic DPRA (kDPRA)	log kmax (units/M-s)	TG 442C
KeratinoSens™	EC <sub>1.5</sub> and IC <sub>50</sub> (μM)	TG 442D
Human cell line activation test (h-CLAT)	EC200 (CD54), EC150 (CD86), CV75 (μg/mL)	TG 442E
U-SENS™	EC150 and CV70 (μg/mL)	TG 442E


<sup>\*</sup>All metrics are required for an individual data type, or the model will not run





#### **Select Model Page**

- Select which model of SARA-ICE to use.
  - The "OECD TG 497 Defined Approach" model is consistent with OECD TG 497 and is acceptable under MAD.
  - The "Extended Model" provides additional functionality to determine hazard, GHS subcategorization, and additional statistics on the ED01 distribution. Data derived from this model are not acceptable for use under MAD.
  - Click "Next" or "View Analysis" to begin analysis, which may take some time to complete.



Use this SARA-ICE model with TG 497. The OECD TG 497 DA (version 1.0) uses defined input data to determine the geometric mean of the  $ED_{01}$  distribution, which is used as the point of departure (PoD) in a quantitative risk assessment for skin sensitization. The use of the OECD TG 497 DA (version 1.0) assumes that substances analyzed in this model are skin sensitizers. Outputs from this model are acceptable under the OECD Mutual Acceptance of Data system.


OECD TG 497 Defined Approach (DA, version 1.0)

#### O Extended Model (version 1.0)

The SARA-ICE Extended Model (not for use within OECD TG 497) provides additional information and model functionality, such as predictions of skin sensitization hazard and GHS sub-categorization, as well as the distribution of the  $ED_{01}$ . Outputs from this model are not acceptable within OECD TG 497 or under the Mutual Acceptance of Data system.








#### **During the Analysis**

- The tool can only analyze one substance at a time, so it will step through each substance provided sequentially.
- The tool will indicate which substance is under analysis by displaying "Running" next to the substance name.
- Results will auto-populate as they are determined, along with a display of the ED<sub>01</sub> distribution as a graph.

# SARA-ICE OECD TG 497 DA (version 1.0) Results Substance CASRN POD ED<sub>01</sub> 5th ED<sub>01</sub> 50th ED<sub>01</sub> 95th ShortName 000-00-0 Running... aChemical 001-00-1

DALICE OECD TG 407 DA (vorsion 1 0) Posults Koy





#### View Analysis – TG 497 DA


#### SARA-ICE

# SARA-ICE OECD TG 497 DA (version 1.0) Results

Substance	CASRN	POD	EI	0 <sub>01</sub> 5th	ED <sub>01</sub> 50th	ED <sub>01</sub> 95th
ShortName	000-00	4,700		780	4,900	25,000
aChemical	001-00 1	1,300		71	1,400	17,000

#### SARA-ICE OECD TG 497 DA (version 1.0) Results Key

- Substance Name of Chemical Substance
- CASRN Chemical Abstracts Service Registry Number (CAS RN or CAS Number)
- POD (Point of Departure) geometric mean of the ED<sub>01</sub> predicated on being a sensitizer
- ED<sub>01</sub> 5th 5th Percentile of the ED<sub>01</sub> distribution (μg/cm<sup>2</sup>)
- ED<sub>01</sub> 50th 50th Percentile of the ED<sub>01</sub> distribution (μg/cm²)
- ED<sub>01</sub> 95th 95th Percentile of the ED<sub>01</sub> distribution (μg/cm²)




#### POD for TG 497 DA use, in µg/cm<sup>2</sup>

Percentiles are provided as additional information on the distribution, but are not required for MAD.


Click "Next" or "Download Analysis" to access Excel or .CSV files of the results.







#### **Download Analysis**


- Click Download to download results as either an Excel or .CSV file.
- Data are populated to the "Substances" tab in the Excel file.
- In Windows, the error shown below may appear after selecting the Excel option. Click "Yes" and Excel will recover the file. A pop-up in Excel will indicate that repairs have been made.











#### **Resources and Help**

• Email <a href="mailto:ICE-support@niehs.nih.gov">ICE-support@niehs.nih.gov</a> for assistance.

SARA-ICE Publication: Reinke et al., 2025: <a href="https://doi.org/10.1016/j.crtox.2024.100205">https://doi.org/10.1016/j.crtox.2024.100205</a>

 OECD Guideline 497: Defined Approaches on Skin Sensitisation: <a href="https://doi.org/10.1787/b92879a4-en">https://doi.org/10.1787/b92879a4-en</a>.



# Acknowledgments



#### The NICEATM Group















Subscribe to NICEATM
News email list





Integrated Chemical Environment



emily.reinke@inotivco.com